Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014]

The authors regret that there in an error in the Funding section of the final published version of this article. The updated text is given below. This work was supported by the Czech Ministry of Health, the institutional support of hospital research [grant number RVO-VFN 64,165], the Czech Ministry of Health grant [grant number AZV NU22-A-150] and by the National Institute for Neurological Research project funded by the European Union - Next Generation EU (Programme EXCELES, ID Project No. LX22NPO5107). The authors would like to apologise for any inconvenience caused. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infectionMultiple Sclerosis and Related DisordersVol. 65PreviewGlobally, there have been almost 300 million confirmed cases of coronavirus disease 19 (COVID-19), including nearly 3.5 million deaths, at the beginning of 2022 ( World Health Organisation, 2022 ). The key element of strategies to reduce the severity of the disease and to suppress the spread of infection is vaccination. COVID-19 vaccines authorised by the European Medicines Agency (EMA) ( European Medicines Agency, 2022 ) have been tested in randomised clinical trials (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021) which were designed to establish efficacy and safety in the general population. Full-Text PDF